ASCIMINIB HYDROCHLORIDE clinical trials

A phase IIIb, multi-center, open-label, treatment optimization study of oral asciminib in patients with Chronic Myelogenous Leukemia in chronic phase (CMLCP) previously treated with 2 or more tyrosine kinase inhibitors

This study is looking at a new way to use an existing medicine called asciminib for people with a type of blood cancer called Chronic Myelogenous Leukemia (CML). It's for patients who have already tried two or more other CML treatments. The main goal is to see how well asciminib works to control the cancer.